Skip to main content

Table 7 Adverse events

From: Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

  Dapagliflozin group (n = 40) Metformin group (n = 40) P value
Any adverse events 6 (15.0) 9 (22.5) 0.57
Hypoglycemia 1 (2.5) 0 (0.0) 1.00
Allergic rhinitis 0 (0.0) 1 (2.5) 1.00
Dry mouth 1 (2.5) 0 (0.0) 1.00
Esophageal varices hemorrhage 1 (2.5)a 0 (0.0) 1.00
Frequent urination 1 (2.5) 0 (0.0) 1.00
Upper respiratory tract infection 0 (0.0) 1 (2.5) 1.00
Interstitial lung disease 1 (2.5)a 0 (0.0) 1.00
Gastroesophageal reflux disease 1 (2.5) 0 (0.0) 1.00
Wound 1 (2.5) 0 (0.0) 1.00
Pharyngitis 0 (0.0) 1 (2.5) 1.00
Dyslipidemia 1 (2.5) 0 (0.0) 1.00
Decrease in appetite 0 (0.0) 1 (2.5) 1.00
Alopecia areata 0 (0.0) 1 (2.5) 1.00
Palpitation 0 (0.0) 1 (2.5) 1.00
Cervical dysplasia 0 (0.0) 1 (2.5)a 1.00
Lung cancer, stage 0 0 (0.0) 1 (2.5)a 1.00
Contusion 0 (0.0) 1 (2.5) 1.00
Diarrhea 0 (0.0) 1 (2.5) 1.00
  1. Data are from treated set population
  2. P values are results by Fisher exact test between groups
  3. aSerious adverse event